Latest Health News

Hydralyte USA reported its strongest monthly sales in May 2025, alongside continued improvement in EBITDA losses, signaling steady progress toward profitability.

Singular Health Group has inked a $1.3 million contract with Provider Network Solutions to deploy its 3DICOM imaging platform across key US states, backed by an $8 million capital raise to fuel national expansion.

EZZ Life Science has launched its US-focused brand EZZDAY with four FDA-registered supplements, marking a major step in its international growth strategy. The company has also begun US-based manufacturing and opened an online store to target American consumers.

HomeCo Daily Needs REIT has recorded a $142 million preliminary valuation gain for the June 2025 quarter, driven by income growth and cap rate tightening, while reaffirming its full-year distribution guidance.

Inventis Limited has agreed to sell its Electronic Circuit Designs division for A$2.4 million, while retaining an option to repurchase the business within a year. The move aims to reduce debt and streamline operations ahead of a planned technology-driven growth phase.

TALi Digital has successfully raised $800,000 through a private placement to fuel the commercialisation of its digital health products aimed at enhancing childhood cognitive attention.

Simble Solutions Limited has resumed trading on the ASX following the announcement of its capital raise details, ending a recent suspension.

Mayne Pharma shareholders have overwhelmingly approved a scheme for Cosette Pharmaceuticals to acquire the company, setting the stage for a pivotal court hearing later this year.

Emyria has landed a multi-year funding deal with Medibank to support its Empax PTSD program at Perth Clinic, marking a first for private insurer-backed psychotherapy in Australia. The company also announces a $4 million capital raise to fuel national expansion.

Viva Leisure has grown from 29 gyms in 2019 to over 480 locations, leveraging proprietary technology and a multi-brand strategy to lead fitness innovation across Australia and beyond.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.

Audeara Limited has reported record unaudited revenue of $3.64 million for the first 11 months of FY25, marking a 14% increase over FY24 and driven by new product launches and international partnerships.